Aegerion Pharmaceuticals to Announce Third-Quarter 2010 Financial Results on Tuesday, November 30
BRIDGEWATER, N.J., Nov. 23, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced that the Company will host a conference call and live audio webcast at 8:30 a.m. ET on Tuesday, November 30 to provide a business update and discuss its third-quarter 2010 financial and operational results.
To listen to the live webcast of the call, please visit the "Investors" section of the Company's website at www.aegerion.com. Individuals may also participate in the call via telephone by dialing (866) 516-3002 or (760) 298-5082. Interested parties unable to join the live call may access an archived version of the webcast on Aegerion's website following the call.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC).
CONTACT: Aegerion Pharmaceuticals, Inc. Corporate Will Lewis, President +1 (908) 704-1300 LaVoie Group, Inc. Investors & Media Amanda Murphy +1 (978) 745-4200 x107 firstname.lastname@example.org